Kornimate/medical-research-clean huggingface dataset:
an exercise intervention for breast cancer patients: feasibility and effectiveness (beat cancer trial; pilot study)

Conditions: Breast Cancer

Summary: "translation" of the current "basic science" information related to physical activity into patient intervention programs is needed. this translation is critical to providing benefit to the maximum number of patients. little is known about the determinants of physical activity among breast cancer patients undergoing hormonal therapy and few studies have attempted to evaluate an exercise behavior change program aimed to improve exercise adherence among such patients. the proposed project will evaluate use of an innovative behavioral and psychosocial intervention to increase physical activity among breast cancer patients.


Eligibility criteria:
inclusion criteria: * female breast cancer patients between the ages of 18 and 70 years of age with a diagnosis of stage i, ii, or iiia breast cancer who are currently taking aromatase inhibitors or selective estrogen receptor modulators for the next 8 months. * english speaking * medical clearance for participation provided by primary care physicians * if the patient has undergone a surgical procedure, must be at least 6 weeks post-procedure exclusion criteria: * diagnosis of dementia or organic brain syndrome * medical, psychological or social characteristic that would interfere with ability to fully participate in program activities and assessments (e.g., psychosis, schizophrenia, etc.) * contraindication to participation in a regular physical activity program. * metastatic or recurrent disease * inability to ambulate * engaged in \>/= 60 minutes of vigorous physical activity or \>/= 150 minutes of moderate plus vigorous physical activity per week during the past month.

Keywords: breast cancer exercise social cognitive theory adherence symptoms body composition
recurrent aa amyloidosis after renal transplantation

Conditions: AA Amyloidosis

Summary: end-stage renal disease related to aa amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. the aim of this study is to evaluate the clinical features of, and risk factors for recurrent aa amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.

aa amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. although end-stage renal disease related to aa amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.

Eligibility criteria:
inclusion criteria: * renal transplantation recipients whose primary renal disease is aa amyloidosis; patients with allograft biopsy-confirmed aa amyloidosis (for study group) and patients with no clinical or laboratory signs of recurrence in the renal allograft (for control group 1) * renal transplantation recipients whose primary diseases are other than aa amyloidosis (for control group 2) exclusion criteria: * patients who are unwilling or unable to consent

Keywords: amyloidosis renal transplantation
bioequivalence of two formulations of biphasic insulin aspart 70 in healthy male subjects

Conditions: Diabetes; Healthy

Summary: this trial is conducted in africa. the aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 70 in healthy male subjects.


Eligibility criteria:
inclusion criteria: * considered generally healthy upon completion of medical history and physical * examination, as judged by the investigator * body mass index (bmi) between 19-29 kg/m\^2 (both inclusive) * minimum body weight of 65 kg * fasting blood glucose between 3.8-6.0 mmol/l * glycohemoglobin (hba1c) below 6.4 % * non-smokers exclusion criteria: * clinically significant abnormal hematology, biochemistry, urinalysis or ecg (electrocardiogram) screening tests, as judged by the investigator * a history of any illness that, in the opinion of the investigator and/or sponsor, might confound the results of the study or pose additional risk in administering the investigational product to the subject * history of or current addiction to alcohol or drugs of abuse as determined by the investigator (positive drug/alcohol abuse screen) * hepatitis b or c * subjects with a first-degree relative with diabetes mellitus * known or suspected allergy to trial product or related products * smoking during the past three months
hand grip strength in chilean adults

Conditions: Hand Grasp

Summary: context hand grip strength (hgs) is an important parameter to assess hand function during the rehabilitation of hand injuries. hgs serves as a clinical predictor of complications after surgery. purpose establish hgs reference values in healthy adult chilean population. study design analytical cross-sectional. method 311 healthy women and men, ages 18 to 65 years participated in the study. hgs was measured with a dynamometer, according to the american society of hand therapists protocol. additionally, anthropometric and labour characteristics were registered. kruskal-wallis test, wilcoxon-mann-whitney test and multiple linear regression were used for data analysis. significance was set at .05. results median hgs in women was 26 kg and 43 kg for men. men demonstrated 3% more hgs on the dominant versus non-dominant hand. women's median hgs was no different between dominant versus non-dominant hand. in men and women, manual labour activity was associated with a higher hgs. the relationships between subject anthropometric measurements and hgs were different in women versus men. conclusions this study determined hgs in chilean healthy adults. results can be used as a reference standard for clinical measures related to illness, injury and rehabilitation.


Eligibility criteria:
inclusion criteria: 1. men and women aged between 18 and 65 years; 2. capable of adopting a seated assessment posture - exclusion criteria: 1. current hand or upper limb pain; 2. history of surgery, fracture, or any condition in the upper limb that could alter hand grip strength

Keywords: hand grip strength; anthropometry; grip; normative values
using artificial intelligence to predict rectal cancer outcomes

Conditions: Rectal Cancer Stage III

Summary: investigator retrospective collect cases during 2010-2021 diagnosed as rectal adenocarcinoma with high quality ct images. local advanced rectal cancer cases were labeled as "disease". nor were defined " normal". using artificial intelligence cnn on jupyter notebook with open phyton code to train and develop models capable to recognizing local advanced rectal cancer. modify the phyton code for better predict rate and help physician to quickly evaluate disease severity for fresh rectal cancer cases.

from 2010.10.1\~2021.12.31, rectal cancer patients with ct3-4 lesion was included. collect high quality ct images with dicom files in tumor segment. ct1-2, low rectal lesions, non-crc cases were not included. non-contrast and artificial defect images were also excluded. ct images were labeled as" diseased " when crm were threatened (\<2mm). all images were labeled according to judgment of 2 specialist. the data were separated into 2 parts. one for ai model training and testing, another for external validation. the training testing dataset was achieved by deep learning neural network and evaluating model accuracy performance. then the model was applied into external validation dataset for real-world testing, evaluating coherent rate between ai and the dr. decision. furthermore, to see the cancer survival outcomes according to ai model prediction results.

Eligibility criteria:
inclusion criteria: * clinical staging t3-4 with high quality ct images. exclusion criteria: * 1. not primary malignancy lesion * 2. not localizing rectum * 3. t1-2 lesion * 4. non contrast or poor quality images
a randomized, double-blind, controlled trial to assess the efficacy of a fortetropin supplement in improving symptoms of osteoarthritis

Conditions: Osteoarthritis

Summary: this is a hybrid, double-blind, randomized, placebo-controlled clinical trial that will last 12 weeks. participants will be randomized into either the intervention product or control group and will consume the test product or control daily. participants will complete study-specific and validated questionnaires at baseline, week 6, and week 12, as well as blood biomarker testing for a lipid panel and high-sensitivity c-reactive protein (hs-crp) at baseline and week 12. osteoarthritis-like symptoms, such as joint pain, inflammation, and reduced mobility will be evaluated at baseline and at each check-in. likert scale responses will be examined from baseline to each check-in. participant responses on product feedback will be presented as % scores. two validated questionnaires, western ontario and mcmaster universities arthritis index (womac) and the numeric pain rating scale (nprs) will also be completed at the questionnaire time points. a full lipid panel and hs-crp measurement will be completed via in-person blood draws.


Eligibility criteria:
inclusion criteria: * men and women aged 50-75 years of age * self-reporting osteoarthritis-like symptoms, experiencing 3 or more of the following symptoms: joint pain, inflammation, reduced mobility, joint swelling, and stiffness. * non-acute osteoarthritis, must have experienced symptoms for longer than 1 year. * generally healthy and don't live with any uncontrolled chronic disease * able to eat eggs (haven't been medically advised to avoid) * willing to stop eating eggs for the 12 week study exclusion criteria: * anyone allergic or intolerant of eggs * anyone who has been advised to avoid eggs * any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * anyone with known severe allergic reactions. * women who are pregnant, breastfeeding or attempting to become pregnant * unwilling to follow the study protocol. * subjects currently enrolled in another clinical study * subjects having finished another clinical study within the last 4 weeks before inclusion * hypersensitivity, allergy, or intolerance against any compound of the test products (e. g. eggs) * recent implantation of a cardiac pacemaker or other active implants * history of or present liver deficiency as defined by quick \< 70% * history of hepatitis b, c, hiv * subjects who are scheduled to undergo any diagnostic intervention or hospitalization which may cause protocol deviations * simultaneous study participation by members of the same household * any diet to lose body weight * eating disorders or vegan diet * present drug abuse or alcoholism
prospective evaluation of combined laparoscopy with co2 intraoperative colonoscopy treatment for colorectal lesions

Conditions: Colorectal Polyps

Summary: the purpose of this study is to evaluate prospectively the usefulness of ic-co2(intraoperative colonoscopy (ic) using carbon dioxide (co2)) in colon and rectal surgical practice, coincident with laparoscopic surgery, and assess whether it provides useful information that influences the type of surgical therapy intended. investigators will further define the safety and extent of bowel distension when using ic-co2.

the purpose of this study is to evaluate prospectively the usefulness of ic-co2(intraoperative colonoscopy (ic) using carbon dioxide (co2)) in colon and rectal surgical practice, coincident with laparoscopic surgery, and assess whether it provides useful information that influences the type of surgical therapy intended. investigators will further define the safety and extent of bowel distension when using ic-co2. furthermore, the investigators will evaluate the therapy and technique of using this combined approach to the treatment of colorectal polyps and other localized, benign lesions of the large intestine. in this study, the colonoscope is used both as a diagnostic and therapeutic tool, and is often used in order to avoid a major bowel resection, yet effectively treat localized lesions of the large intestine. the hypothesis of this study is that ic-co2 will provide useful information which does affect surgical decision making at the time of operation, and that it is safe and does not result in any significant bowel distention during or immediately after the procedure. we additionally hypothesize that certain localized lesions of the intestines may be treated using a combined laparoscopic-ic-co2 approach to effectively treat the underlying disease, minimize risks to the patient, and avoid a major bowel resection.

Eligibility criteria:
inclusion criteria: * all patients (male and female) greater than 18 years of age who undergo a laparoscopic surgical procedure that utilizes intra-operative colonoscopy will be approached to participate in this study exclusion criteria: * patients under 18 year of age * patients with severe renal diseases * ascites * copd (severe) * liver insufficiency (severe) with coagulopathy * dialysis * sleep apnea * patient pregnant * multiple previous surgeries * subject is incapable of understanding the informed consent

Keywords: laparoscopy co2 colonoscopy intraoperative co2 colonoscopy combined lap-co2 procedure
2d speckle-tracking echocardiography in chemotherapy-induced cardiomyopathy with cardiovascular risk factors

Conditions: Cardiomyopathy Due to Drug; Breast Cancer; Cardiovascular Risk Factor

Summary: the aims of this study is to evaluate the role of 2d speckle-tracking echocardiography in diagnosis chemotherapy related left ventricular dysfunction in breast cancer patients with cardiovascular risks

chemotherapy induced cardiomyopathy is a serious adverse effect of anticancer treatments with poor long-term prognosis. in addition to the cumulative dose of anthracycline and trastuzumab, cardiovascular risks have been proven to be the "second hit" when dealing with chemotherapy related cardiomyopathy in breast cancer patients. speckle-tracking echocardiography have had robust evidence in diagnosis the early stage of left ventricular dysfunction in various types of cancer treated by cardiotoxicity drugs. however, data is still lacking regarding the role of speckle-tracking echocardiography in breast cancer patients with cardiovascular risk

Eligibility criteria:
inclusion criteria: * breast cancer patients treated by anthracycline and/or trastuzumab * have at least one of these cardiovascular risks: age \> 60, hypertension, atrial fibrillation, diabetes mellitus, dyslipidemia, chronic kidney disease, obesity, family history of cardiovascular diseases. exclusion criteria: * left ventricular ejection fraction \< 50% before chemotherapy * chronic heart failure with nyha functional class \>= ii * significant valvular stenosis/regurgitation * acute heart failure due to acute coronary syndrome during follow-up
exoskeleton for post-stroke recovery of ambulation

Conditions: Conditions

Summary: to determine the effect of using a robotic exoskeleton to allow walking practice after stroke, compared to usual physiotherapy care, on recovery of walking ability and secondary outcomes.

participants admitted to inpatient stroke rehabilitation for physiotherapy services will be randomly assigned to either the exoskeleton program or usual care program. individuals in the exoskeleton program will have their usual physiotherapy sessions replaced with the exoskeleton intervention. the exoskeleton will allow standing and walking from the first sessions in rehabilitation, as the exoskeleton provides the physical support to allow walking in full weight-bearing without being limited by therapist fatigue and lifting requirements. individuals in the usual care program will receive standard physiotherapy care, which is individualized and hands-on with their therapist to regain walking, mobility, and independent function. both groups will be conducted 3-5 days a week, 30-60 minutes per session until discharge (to a maximum of 8 weeks). participants will be assessed at baseline, discharge, and 6-months after starting rehabilitation.

Eligibility criteria:
inclusion criteria: * have been admitted to a hospital unit for stroke treatment * stroke within last 3 months * one-sided hemiparesis * 19 years or older * requires 2-person assist to walk * able to communicate and follow instructions * prescribed to receive physiotherapy care exclusion criteria: * stroke of non-vascular origin (e.g. tumour, infection) * significant musculoskeletal or other neurological condition * co-morbidities that would preclude activity * pregnant * unable to walk prior to stroke * \ 74 inches in height * \>220 pounds in weight * joint contractures or spasticity that would limit safe use of the ekso exoskeleton

Keywords: exoskeleton stroke walking rehabilitation
evaluation of desensitization therapy and re-treatment of eye movement information [emdr] in patients with post-traumatic stress disorder [ptsd]

Conditions: Post-traumatic Stress Disorder

Summary: this research aims to confirm that the therapeutic effect of emdr is associated with changes in the interaction between cognitive function and emotional stimuli in ptsd patients compared to a controlled therapy in a randomized, single-blind study.on the other hand, this study aims to observe neuronal and cognitive correlates related to emdr therapy compared to a control therapy. this investigation would improve the understanding of the mechanisms of action of the emdr, still unknown to date.


Eligibility criteria:
inclusion criteria: * patient diagnosed with ptsd according to dsm 5 criteria (apa 2013) related to a single traumatic event, * aged 18 to 65 years, * signed informed consent. * patient with social security affiliation or state medical aid (ame) exclusion criteria: * neurological disorders * no other major psychiatric disorders than ptsd (dsm 5) * severe and/or unstable somatic pathologies, * patient not affiliated with social security, * patient hospitalized under stress in psychiatric care at the decision of the state representative or in psychiatric care at the request of a third party, * patient under guardianship, * patient participating in parallel with other biomedical research, * change of antidepressant during the last three months, * patient not fluent in french * mr-specific criteria for not inclusion: * women of childbearing age without effective contraception or a positive pregnancy test, * patients carrying pacemakers or electrical or electronic devices, clips or metal prostheses, * subjects with neurological disorders, cerebral abnormalities or suffering from claustrophobia.

Keywords: eye movement information- post-traumatic stress disorder
the clinical efficacy of three oral hygiene regimens using a manual toothbrush, toothpaste and a mouthwash in controlling dental plaque and gingivitis

Conditions: Dental Plaque; Gingivitis

Summary: the objective of this clinical research study is to assess the efficacy of three oral hygiene multi-component regimens encompassing the use of a manual toothbrush, toothpaste and a mouthwash in controlling established dental plaque and gingivitis.


Eligibility criteria:
inclusion criteria: 1. male and female subjects, ages 21-70, inclusive. 2. availability for the six-week duration of the study. 3. good general health. 4. minimum of 20 uncrowned permanent natural teeth (excluding third molars). 5. initial gingivitis index of at least 1.0 as determined by the use of the loe and silness gingival index. 6. initial plaque index of at least 1.5 as determined by the use of the quigley and hein plaque index (turesky modification). 7. signed informed consent form. exclusion criteria: 1. presence of orthodontic bands. 2. presence of partial removable dentures. 3. tumor(s) of the soft or hard tissues of the oral cavity. 4. advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). 5. five or more carious lesions requiring immediate restorative treatment. 6. use of antibiotics any time during the one month prior to entry into the study. 7. participation in any other clinical study or test panel within the one month prior to entry into the study. 8. pregnant women or women who are breast feeding. 9. dental prophylaxis received in the past two weeks prior to baseline examinations. 10. history of allergies to oral care/personal care consumer products or their ingredients. 11. on any prescription medicines that might interfere with the study outcome. 12. an existing medical condition which prohibits eating or drinking for periods up to 4 hours. 13. history of alcohol or drug abuse
postprandial efficacy of probiotic fruit beverages on glucose tolerance and insulin resistance

Conditions: Postprandial Hyperglycemia

Summary: consumption of polyphenol-rich fruits and vegetables may improve the postprandial glucose and insulin responses and hence promote well-being. it has previously been observed that consumption of a bilberry drink decreases the postprandial insulin demand. in the present study, the impact of probiotic fruit beverages with different polyphenol profiles on the postprandial levels of glucose and insulin, were investigated.


Eligibility criteria:
inclusion criteria: * healthy, not on medication, non-allergic, individuals aged 18-65 years old, having a bmi between 20-30 kg/m2 and also maintaining stable body weight, i.e. less than 5% weight change in the last three months before the study. exclusion criteria: -
huangqi guizhi wuwu decoction in ckd stage 2-4 diabetic nephropathy

Conditions: Diabetic Nephropathies

Summary: this is a prospective, open, multicenter clinical trial.the objective of this study is to evaluate the efficacy and safety of huangqi guizhi wuwu decoction in patients with ckd stage 2-4 diabetic nephropathy.

the incidence rate of chronic kidney disease is 10.8% in china. the incidence rate of diabetic nephropathy has increased year by year, and now it has become the first cause of uremia. therefore, the treatment of diabetic nephropathy can delay the progression of renal function and is of great value and significance in reducing uremia. huangqi guizhi wuwu decoction is a traditional chinese medicine decoction. previous studies have shown that it is effective in the treatment of diabetic nephropathy. in this study, there were 2 hospitals participating in. we planned to enroll 100 participants, who will be divided into the huangqi guizhi wuwu decoction group (experimental group) and the dapagliflozin group (control group). all participants will take medication for 12 weeks, and investigators will follow up participates at weeks 0, 2,4, 6, 8,12.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed as diabetic nephropathy 2. tcm syndrome differentiation is qi deficiency and blood stasis type 3. male or female, 18≤age≤75 4.25ml/（min.1.73m2）≤ egfr\<90ml/（min.1.73m2） 5.24-hour urine protein ration ≤3.5g/24h 6.the participants must be capable of understanding and comply with the protocol and sign a written informed consent document exclusion criteria: 1. exposure to immunosuppressors, glucocorticoid，without a one weeks washout period 2. urinary tract infection (leukocytes in urinary sediment \> 5 / hp) 3. serum potassium \> 5.5 mmol/l 4. serum albumin \< 30g/l 5. pregnant or lactating women, and participants (including males) who were unable or unwilling to take adequate contraception during the study period 6. having comorbidities that affect the progression of diabetic nephropathy (including but not limited to malignant tumors, systemic autoimmune diseases, liver cirrhosis) 7. participating in another clinical trial 8. investigators do not think it suitable for a participant to join this study

Keywords: diabetic nephropathy,huangqi guizhi wuwu decoction (ckd2-4)